SEC Form 4 · accession 0001144204-16-106844
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Gill
Officer — President and CEO · Director
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.20 | Jun 1, 2016 | A | 100,000 | A | — | May 31, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This award vests over three years, with one third of the options vesting on the first, second and third anniversaries of the date of grant. This award may be subject to acceleration in certain circumstances.